Sanofi

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which will be evaluated… Read More

#Business & Investment #News #Trending News

#Fast Track designation #FDA #mRNA #Sanofi #Vaccines

Chlamydia vaccine candidate granted fast track designation

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need.  The chlamydia vaccine candidate… Read More

#News #Regulatory

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News

Multiple myeloma
#Japan #Myeloma #Phase III trial #Regulatory #Sanofi

Sarclisa approved in Japan for newly diagnosed multiple myeloma

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study.  Olivier Nataf, Global Head of Oncology at Sanofi,… Read More

#News #Regulatory

Monoclonal antibodies
#Inflammatory Bowel Disease #Monoclonal antibodies #Phase II trial #Sanofi #Teva

New data indicate duvakitug could “transform” IBD treatment

Sanofi and Teva Pharmaceuticals have revealed new results from their Phase IIb study of duvakitug for ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).   The results were shared in two oral presentations at the 20th Congress of the… Read More

#News #Trending News

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult… Read More

#News #Regulatory

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

#Chronic obstructive pulmonary disease (COPD) #Monoclonal antibodies #Regeneron Pharmaceuticals #Sanofi

First biologic drug for COPD gets green light in US and China

Dupixent (dupilumab) has become the first biologic medicine for chronic obstructive pulmonary disease (COPD) in the US and China. Sanofi and Regeneron secured approvals from both the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) in the same week. It is approved for adults with… Read More

#News #Regulatory

FDA headquarters
#FDA #Monoclonal antibodies #Myeloma #Oncology #Sanofi

FDA approves Sarclisa combination for multiple myeloma

The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma. It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated… Read More

#News #Regulatory

Monoclonal antibody
#Dermatology #Monoclonal antibodies #Orphan drugs #Sanofi

Biologic achieves improvements in bullous pemphigoid

A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More

#News

EMA concept
#Chronic obstructive pulmonary disease (COPD) #European Medicines Agency #Sanofi

Dupixent first targeted therapy for COPD approved in EU

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils. The approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist… Read More

#News #Regulatory #Trending News

Mouse in laboratory
#Animal models #Charles River #Preclinical development #Sanofi

New project hopes to reduce the use of animals in drug research

Charles River Laboratories has announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets. The VCG collaboration… Read More

#News

Assoc Prof Tim Mercer and researcher Dae Jong Han, UQ
#Australia #Bioproduction #mRNA #Sanofi #TriLink BioTechnologies #United States #University of Queensland

As mRNA demand surges, Australia and US launch new facilities

As demand for mRNA continues to surge, two new facilities have been launched to boost production in Australia and the US. Work is underway at The University of Queensland’s (UQ) BASE facility which has become Australia’s leading provider of mRNA for research and pilot studies since… Read More

#News

#AI #BioMap #Biotherapeutics #Collaboration #Sanofi

Collaboration to develop AI modules for biotherapeutics 

BioMap has entered a strategic collaboration with Sanofi to co-develop AI modules for biotherapeutic drug discovery, leveraging BioMap’s AI platform.  Traditional AI methods require vast amounts of labeled data to make accurate predictions. However, in life science, labeled data are often in short supply. BioMap’s foundational models… Read More

#News

#AstraZeneca #Business #Pfizer #Quarterly review #Regulatory #Sanofi

Drug discovery quarterly review: Second quarter 2023  

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates   Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational… Read More

#Business & Investment #Exclusive Content #Regulatory

Vaccine production
#Collaboration #Immunology / Virology & Vaccines #Lifera #Manufacturing #Sanofi #Saudi Arabia

Partners agree to boost vaccine accessibility in Saudi Arabia

Saudi Arabian company Lifera is partnering with Sanofi and Arabio to strengthen local manufacturing of vaccines in Saudi Arabia. Under the terms of the Memorandum of Understanding (MOU), Lifera, Sanofi and Arabio will explore opportunities for collaboration to help advance Saudi Arabia’s vaccines localisation strategy through… Read More

#News